Title: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Authors: Fizazi, Karim ×
Scher, Howard I
Molina, Arturo
Logothetis, Christopher J
Chi, Kim N
Jones, Robert J
Staffurth, John N
North, Scott
Vogelzang, Nicholas J
Saad, Fred
Mainwaring, Paul
Harland, Stephen
Goodman, Oscar B
Sternberg, Cora N
Li, Jin Hui
Kheoh, Thian
Haqq, Christopher M
de Bono, Johann S
COU-AA-301 Investigators #
Contributors: Sch√∂ffski, Patrick
Issue Date: Oct-2012
Publisher: Lancet Pub. Group
Series Title: The Lancet Oncology vol:13 issue:10 pages:983-992
Article number: 10.1016/S1470-2045(12)70379-0
Abstract: Abiraterone acetate improved overall survival in metastatic castration-resistant prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-controlled phase 3 study. Here, we present the final analysis of the study before crossover from placebo to abiraterone acetate (after 775 of the prespecified 797 death events).
ISSN: 1470-2045
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science